Standard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Inc. reported Q2 2026 revenue of $20.1 million, a 7.6% decrease year-over-year, with improved adjusted EBITDA loss by 84%. The company is progressing toward a merger with Treeline Biosciences anticipated to close by the end of 2026, aiming to enhance shareholder value through exposure to a promising therapeutic pipeline. Operating…